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PORCINE VALVES ARE 
REENDOTHELIALIZED BY 
HUMAN RECIPIENT 
ENDOTHELIUM IN VIVO 
The degeneration of human allogeneic and porcine xenogeneic heart valves has not 
been clearly understood. The question is whether the observed ioss of function and 
calcification is primarily an immunologic process or a mechanical process or is 
influenced by both factors. In the current study, we looked at explanted xenogeneic 
heart valves for the presence of recipient endothelium. Explanted valves were shock 
frozen and stored at -80°C before use. They were subsequently examined by 
immunohistochemical staining with a variety of monoclonal antibodies. Xenogeneic 
valves showed clearly positive resuits for the human major histocompatibility 
complex class I and class II antigens and morphologically showed a thin layer of 
viable endothelium restricted to the annular region of the valve. Additionally, they 
were also positive for intercellular adhesion molecule-1 and the H-Y antigen. 
Although the xenogeneic valves were significantly degenerated, the endothelium was 
clearly defined and could be identified immunohistochemically as being of recipient 
origin. The gratis remained negative for endothelial cell-leukocyte adhesion mole- 
cule-1 and factor VIII. These data allow speculation on whether reendothelialization 
of valvular grafts with recipient endothelium is a normal repair mechanism in vivo. 
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V alvular replacement has come of age. Lam, /kram, and Munnell 1 first tried the use of a 
homograft in the descending aorta of dogs in 1952. 
The nonfunctional aortic leaflets degenerated and 
fibrosed. It soon became apparent hat allografts 
could only remain functional when subjected to a 
functional work load. 2 Despite improved conserva- 
tion and treatment, he degeneration of allografts 
still poses a major clinical problem. After about 7 
years, allografts begin to show signs of wearing, 
calcification, and tearing. It is quite obvious that 
mechanical damage does play a role, but to what 
extent do immunologic factors contribute to the 
chronic loss of valves? 
The immunogenicity of valves has been the sub- 
ject of study by several groups, including ours. 3-7 
From the Institute of Immunology a and Hospital of Cardiovas- 
cular Surgery, c University of Kiel, and Hospital of Heart 
Surgery, b University of Lübeck, Germany. 
Received for publication April 21, 1994. 
Accepted for publication Sept. 30, 1994. 
Address for reprints: Nicholaus Zavazava, PhD, Institute of 
Immunology, University of Kiel, Brunswikerstr. 4, 24105 Kiel, 
Germany. 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $3.00 + 0 12/1/61027 
702 
From these studies it has become apparent hat 
murine and human valves express major histocom- 
patibility complex (MHC) antigens and that cryo- 
preservation does not abolish their immunogenic- 
ity. 3 Our recent data showed that human valvular 
endothelium constitutively expresses class I and 
class II antigens. After stimulation with interferon 
gamma they show increased expression of adhesion 
molecules. These studies point to the fact that valves 
can sensitize the recipient and thus lead to acceler- 
ated graft degeneration. Experiments o  mixed cell 
reactions, where vascular endothelium was used to 
stimulate T cells, showed enhanced allogeneic reac- 
tion in comparison with that of peripheral blood 
lymphocytes. 7 Allografts or xenografts can sensitize 
the recipient only if a viable endothelial layer is 
present. Some studies have shown that cryopreserved 
valves still possess viable cells, s but the methods used 
to test cell viability require further improvement. 
In the current study we looked at the possibility of 
the in vivo reendothelialization f xenografts. In 
these studies we used immunohistochemical staining 
of explanted and nonfunctional xenografts. 
Materials and methods 
Explanted valves. Heart valves were obtained when 
insufficient xenografts (n = 4) or allografts (n = 5) were 
replaced, at transplantation, and at cardiac retransplanta- 
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tion (n = 2). The explanted grafts were removed normally 
after at least 7 years. The valves were quickly shock frozen 
in liquid nitrogen until further use. 
Fresh porcine valves. Porcine hearts were obtained 
from the slaughterhouse immediately fterthe animals 
were killed and delivered to the laboratory at 4 ° C. The 
aortic, pulmonary, and mitral valves were removed and 
quickly shock frozen. Five-micrometer sections were cut 
and used for immunohistochemical st ining as control 
specimens for the explanted xenogeneic grafts. 
Antibodies. The clone for the W6/32 monoclonal nti- 
body (anti-human leukocyte antigens A, B, and C) was 
obtained from the American Type Cell Culture. The clone 
was grown in culture and the supernatant purified over a 
protein A colurnn (Pharmacia, Uppsala, Sweden). The 
antibody was concentrated to 1 ~g/ml before use. The 
anti-DR antibody was purchased from Becton Dickinson, 
Oxnard, Calif. The anti-intercellular adhesion m lecule-1 
(ICAM-1), anti-endothelial cell-leukocyte adhesion mol- 
ecule-1 (ELAM-1), anti-factor VIII (F-VIII), and anti- 
H-Y antibodies were obtained from Immunotech, France. 
Immunohistochemical staining of explanted valves. 
Five-micrometer sections of explanted valves were fixed in 
acetone for 10 minutes and subsequently washed for 2 
minutes in Tris-buffered saline. Antibodies were titrated 
between 1/10 and 1/50 for optimal stains. The sections 
were stained by the alkaline phosphatase-anti-alkaline phos- 
phatase staining technique, as we previously described in 
more detail elsewhere. 7 Only the sections stained with the 
ME1 were developed with the peroxidase enzyme. 
Results 
There was virtually no positive stain of the fresh 
porcine valves obtained from the slaughterhouse 
with any of the antibodies used. The anti-DR anti- 
body had minimal affinity for the coUagen fibers and 
stroma, but remained negative for porcine endothe- 
lial cells. The four antibodies, W6/32, anti-ICAM-1, 
anti-H-Y, and anti-DR, were positive on allografts 
7 as we previously reported. However, surprisingly, a 
monolayer of endothelial cells was clearly detectable 
on the xenografts. In Fig. 1, the anti-class I antibody 
strongly stained a monolayer of cells that had oval- 
shaped cell nuclei. These cells were morphologically 
identified as endothelial cells. Further evidence that 
the cells were endothelial was the observation that 
the cells were only identified on the annular egion 
of the valves and not within the graft. This suggests 
that the cells that characteristically infiltrate the 
graft and would be distributed within the leaflets 
were not mononuclear. All xenografts studied (n = 
4) were found to be positive for endothelial cells. 
Additionally, the section in Fig. 1 shows the 
degeneration of the xenogeneic graft. Patches of 
calcification are clearly visible. Consequently the 
valves were difficult to cut in cryostat sections. The 
valves were hard and leit like plastic pads. 
Fig. 1. Human endothelium on degenerated explanted 
valvular porcine xenograft. Five-micrometer section of 
porcine xenograft is stained with W6/32 monoclonal nti- 
body that stains human class I antigens (anti-human 
leukocyte antigens A, B, and C). Monolayer of cells that 
have oval-shaped cell nuclei and strongly express class I 
antigens is observed. These cells are morphologically 
endothelial. Collagen fibers of valve are no longer intact 
and show signs of calcification (arrows), visible as white 
patches dissipated on graft (original magnification ×366). 
The sections were further stained with the H-Y 
antibody. A fine monolayer was stained (Fig. 2, A) 
confirming that the cells were endothelial, as we 
previously reported. 7 For comparison, we stained a 
homograft to show the endothelium and the inten- 
sity of expression of the H-Y antigen (Fig. 2, B). The 
homograft had been obtained from an explanted 
heart that was insufficient. Further evidence for the 
presence of human endothelial cells on xenogeneic 
grafts was provided by the anti-DR antibody (Fig. 
3). This antibody also stained the ndothelial cells. 
This was expected inasmuch as we had previously 
reported on the weak expression of MHC class II 
antigens by endothelial cells. The ICAM-1 antibody 
stained strongly, whereas the ELAM-1 and F-VIII 
antibodies remained negative. These data are sum- 
marized in Table I. 
Discussion 
The degeneration of xenogeneic and allogeneic 
valve grafts is a serious clinical problem that is orten 
accompanied by severe heart problems. Some of the 
reasons that lead to degeneration could be mechan- 
ical damage, but immunologic processes may play a 
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Fig. 2. A, Immunohistochemical st ining of porcine valves with anti-H-Y antibody. Further evidence that 
monolayer identified in Fig. 1 is human endothelium is provided by H-Y antibody. Monolayer is also 
identified that is continuous on surface of valve. Signs of calcification are also visible here as small white 
patches below endothelial monolayer (original magnification ×180). B, Homograft stained with H-Y 
antibody. Section was not stained with hemalaum solution to allow better differentiation f endothelium. 
Strongly stained monolayer of endothelial cells is clearly visible. Tissue of homograft was also weil 
maintained, showing no signs of degeneration (original magnification × 180). 
significant role. Cryopreservation retains antigenic- 
ity by maintaining cell viability of fibroblasts and 
endothelial cells. Syngeneic tissue calcified rar less 
than allogeneic tissue, suggesting immunologic pro- 
cesses. 9 The aim of the current s udy was to examine 
the possibility of reendothelialization of xenografts 
with human endothelium. Our data show that xeno- 
geneic grafts can be reendothelialized by human 
endothelium. To our knowledge this is the first 
description of reendothelialization f porcine xe- 
nografts by human endothelium. 
O'Connell and colleagues 1° have previously 
shown that endomyocardium of cardiac grafts 
can be reendothelialized by recipient endothelium 
in at least 30% of cases after cardiac transplantation. 
These data suggest hat reendothelialization is a 
natural repair mechanism after immunologic or 
mechanical damage and injury. The endothelial cell 
distribution was limited to the annular egion of the 
leaflet. Presumably these cells originated from the 
aorta wall and wandered onto the porcine graft. The 
porcine valve matrix is obviously suitable for human 
endothelial cell adhesion. 
Other groups have reported degeneration of 
valves in children 6 and elderly patients. We exam- 
ined the immunogenicity of human valvular endo- 
thelial cells in a recent paper. 7 In this report we 
described the expression of MHC antigens and that 
of adhesion molecules on valvular endothelium. 
Antigen expression is a prerequisite for the immu- 
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Table I. Summary of antigen expression by human 
endotheIium found on xenogeneic valvular 
bioprotheses 
Expression intensity 
Antigen on xenografis 
MHC class I + + + 
MHC class I1 + + 
ICAM-1 + + 
ELAM-1  
H-Y  + + 
F-V I I I  
+ + +, Very strong expression; ++, strong expression; - , no expression. 
nologic reactions that lead to degeneration of hu- 
man valves. Cryopreserved valves with a viable 
endothelium can potentially present antigen to host 
T and B cells eliciting an immunologic reaction. Our 
previous data showed that valvular endothelium can 
stimulate T cells in a mixed cell reaction. Although 
the expression of class II antigens was low, cell 
stimulation was more enhanced than that by periph- 
eral blood lymphocytes. However, Lupinetti and 
associates 4 failed to show a direct link between 
antigenicity and immunogenicity. These findings 
suggest that we may never be able to predict he fate 
of an allograft despite available knowledge on cell 
viability and immunogenicity before implantation. 
The question that arises from our data is how 
reendothelialization f valves occurs in vivo. Does 
endothelial cell damage occur beforehand or can 
donor and recipient endothelium coexist? A careful 
study of the xenografts shows that the only endothe- 
lium present on the valves is positively stained by 
anti-human antibodies. Damaged donor endothe- 
lium is likely to be progressively replaced by recip- 
ient endothelium. Studies on microchimerism on 
recipient valvular allografts are now under way. 
Recent data by Eberl and associates 11show the 
differences in the in vitro reendothelialization suc- 
cess of bioprotheses that hav.e been fixed by different 
techniques. Should the bioprotheses be fixed in such 
a way that they can promote reendothelialization in 
vivo, we may be able to make the in vitro reendo- 
thelialization unnecessary by promoting the in vivo 
process. The potential of viable allografts to survive 
for a long time is supported by the data by Ross, 
Jackson, and Davies 12that show autologous pulmo- 
nary valves placed in the aortic position can success- 
fully survive without any signs of degeneration. It 
appears therefore that factors contributing to the 
degeneration of bioprotheses are not 0nly mechan- 
ical and immunologic, but also that the preceding 
Fig. 3. Human endothelium on xenografts expresses class 
II antigens. Anti-DR antibody was used to examine 
whether human endothelium found on reendothelialized 
valvular xenografts expresses class II antigens. Positively 
stained monolayer is identified. Stain is weak, showing 
that human endothelium expresses low levels f class II 
antigens (original magnification x90).
preservation contributes much to their rate. In ad- 
dition, Grabenwoger and colleagues 13have recently 
pointed out the significance of phagocytosis n the 
subsequent degeneration of bioprotheses. This sup- 
ports the data that enzymes present in explanted 
valves were found to be strong in proteolytic activ- 
i ty .  14 
The antigenicity of valves was demonstrated very 
early by our group and others. 5' 15 Although the 
degeneration of allografts and xenografts has been 
clinically documented, the immunologic processes 
underlying this are poorly understood. Our data 
show that human endothelial cells constitutively 
present on allografts express MHC antigens and 
some adhesion molecules. We also show that al- 
though valvular grafts degenerate with time, a fine 
layer of recipient endothelial cells is present. This 
suggests that reendothelialization f valvular grafts 
is a natural repair and replacement procedure that 
occurs in vivo. In another study we showed that 
during acute rejection f cardiac grafts a mononu- 
clear cell infiltration within the valvular allograft can 
be observed (data not shown). The presence of these 
cells suggests that valves are immunogenic and are 
recognized as foreign antigen just like any other 
tissue. In conclusion, we suggest that the degenera- 
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tion of valves after implantation may not only be 
caused by mechanical reasons, but also by local 
immunologic processes that occur on the grafts. 
Further reendothelial ization of porcine valves ap- 
pears to be a natural repair process after xenogenic 
valve implantation. 
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